| Citation: |
LIU Baojie, REN Li. Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma[J]. Journal of Clinical Medicine in Practice, 2024, 28(11): 41-44. DOI: 10.7619/jcmp.20240423
|
To investigate the impacts of drug administration processes on comfort, tolerability and adverse events in patients with chemotherapy for multiple myeloma.
A total of 113 patients with chemotherapy for multiple myeloma were randomly divided into control group (n=56) and observation group (n=57). The control group was treated with conventional drug administration procedures, while the observation group was treated with bortezomib subcutaneously by an optimized drug administration process. Comfort level, tolerability, adverse events and satisfaction rate for injection were compared between the two groups before and after intervention.
After intervention, the observation group scored higher on the General Comfort Questionnaire (GCQ) for physiological dimension of (24.59±2.73), psychological dimension of (25.64±2.29), sociocultural dimension of (22.64±2.05), environmental of (11.79±1.37), and total score of (79.21±6.81) than (21.68±2.67), (22.05±2.16), (18.11±1.74), (9.42±1.46) and (63.52±6.34) respectively in the control group. Total chemotherapy course was (6.02±1.08) cycles in the observation group, which was less than (7.86±1.59) cycles in the control group, with a chemotherapy discontinuation rate of 8.77% versus 37.5%, and the full-dose and full-schedule chemotherapy completion rate of 96.49% versus to 82.14% between observation group and control group, and all the differences were statistical significant (P < 0.05). The overall incidence of liver-kidney function damage, thrombocytopenia, and peripheral neuropathy during medication administration was 3.51% in the observation group, which was significantly lower than 16.07% in the control group (P < 0.05). The satisfaction rate for injection in the observation group was 94.74%, which was significantly higher than 78.57% in the control group (P < 0.05).
Optimizing the drug administration process can improve patient's comfort and tolerability during chemotherapy for multiple myeloma, reduce the incidence rate of adverse reactions, and has a high satisfaction rate for injection.
| [1] |
GUZDAR A, COSTELLO C. Supportive care in multiple myeloma[J]. Curr Hematol Malig Rep, 2020, 15(2): 56-61. doi: 10.1007/s11899-020-00570-9
|
| [2] |
GENTILE M, MORABITO F, MARTINO M, et al. Chemotherapy-based regimens in multiple myeloma in 2020[J]. Panminerva Med, 2021, 63(1): 7-12.
|
| [3] |
MATEOS M V, SONNEVELD P, HUNGRIA V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(8): 509-518. doi: 10.1016/j.clml.2019.09.623
|
| [4] |
ASHRAFI F, MOGHADDAS A, DARAKHSHANDEH A. Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma[J]. J Res Pharm Pract, 2020, 9(1): 56-59. doi: 10.4103/jrpp.JRPP_18_82
|
| [5] |
汪英颖, 刘尚勤. 多发性骨髓瘤诊治指南解读(2018年)[J]. 临床内科杂志, 2018, 35(7): 503-504. doi: 10.3969/j.issn.1001-9057.2018.07.024
|
| [6] |
李芳, 陈玲燕, 罗菊. 思维场疗法结合舒适护理在多发性骨髓瘤化疗患者中的应用[J]. 齐鲁护理杂志, 2022, 28(15): 101-104. doi: 10.3969/j.issn.1006-7256.2022.15.034
|
| [7] |
LIU Z Q, XIA H L, LI C J, et al. Incidence and risk of peripheral neuropathy caused by intravenous and subcutaneous injection of bortezomib[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27(5): 1654-1663.
|
| [8] |
王科, 苏梅芳, 王萌, 等. 硼替佐米不同给药途径治疗多发性骨髓瘤的疗效及其与周围神经病变的相关分析[J]. 临床内科杂志, 2022, 39(12): 846-847. doi: 10.3969/j.issn.1001-9057.2022.12.016
|
| [9] |
LI F, YAO F S, ZHU X J, et al. A randomized phase Ⅱ, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients[J]. J Cancer Res Clin Oncol, 2019, 145(9): 2343-2355. doi: 10.1007/s00432-019-02967-3
|
| [10] |
钱晨, 张柳柳, 顾连兵, 等. 多学科合作模式在优化术中腹腔化疗给药流程中的应用[J]. 中华现代护理杂志, 2023, 29(14): 1909-1912. doi: 10.3760/cma.j.cn115682-20220406-01627
|
| [11] |
周江燕, 谢珺, 殷丹, 等. 部位轮换定时定位注射卡应用于多发性骨髓瘤患者皮下注射中的效果[J]. 国际护理学杂志, 2023, 42(3): 444-446. doi: 10.3760/cma.j.cn221370-20210626-00109
|
| [12] |
曹红花, 吴娜, 贺鸣, 等. 皮下注射硼替佐米为主化疗方案治疗多发性骨髓瘤[J]. 昆明医科大学学报, 2019, 40(5): 49-52. doi: 10.3969/j.issn.1003-4706.2019.05.009
|
| [13] |
柏杨, 占美, 魏春燕, 等. 皮下注射硼替佐米的有效性和安全性循证评价[J]. 中国医院药学杂志, 2019, 39(13): 1358-1362, 1374. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201913010.htm
|
| [14] |
梁艳, 周海燕, 叶小聪, 等. Z径路法结合留置气泡技术减轻注射用鼠神经生长因子肌内注射时疼痛的效果评价[J]. 护士进修杂志, 2017, 32(7): 651-652. https://www.cnki.com.cn/Article/CJFDTOTAL-FSJX201707028.htm
|
| [15] |
曾卫强, 曲云婷, 闫其星, 等. 抗肿瘤药物药学监护路径的建立和应用[J]. 中国药房, 2016, 27(35): 5017-5020. doi: 10.6039/j.issn.1001-0408.2016.35.41
|
| [16] |
刘璐, 蒋开明. 腹部轮换定时定位注射卡在多发性骨髓瘤患者皮下注射中的应用[J]. 中华现代护理杂志, 2019, 25(25): 3268-3271. doi: 10.3760/cma.j.issn.1674-2907.2019.25.023
|
| [17] |
蒋海华, 粟东云, 奉赛芝, 等. Z型注射法结合留置气泡技术在注射氟维司群患者中的应用效果[J]. 解放军护理杂志, 2017, 34(23): 74-76. https://www.cnki.com.cn/Article/CJFDTOTAL-JFHL201723025.htm
|
| [18] |
王珣, 徐岚, 赵素芳, 等. 硼替佐米腹部皮下注射治疗多发性骨髓瘤的疗效及不良反应的护理[J]. 中华现代护理杂志, 2018, 24(12): 1450-1453. doi: 10.3760/cma.j.issn.1674-2907.2018.12.022
|
| [19] |
李媛, 傅荣, 叶红芳, 等. 硼替佐米皮下注射治疗多发性骨髓瘤给药流程设计与实践[J]. 护理学杂志, 2015, 30(23): 12-14. https://www.cnki.com.cn/Article/CJFDTOTAL-HLXZ201523005.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: